Press release
Oncolytic Adenovirus Market is projected to reach USD 389 million by 2034
Oncolytic Adenovirus
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71266
Oncolytic adenoviruses are genetically engineered viruses designed to selectively infect and kill cancer cells while stimulating systemic antitumor immune responses. Their dual mechanism-direct oncolysis + immune activation-positions them as one of the most promising categories in next-generation oncology therapeutics. As immunotherapy resistance becomes more common in advanced cancers, oncolytic viruses are increasingly considered for combination regimens with checkpoint inhibitors, CAR-T, TCR therapies, and targeted biologics.
Key Market Highlights
• 2024 Market Size: USD 124 million
• 2034 Forecast: USD 389 million
• CAGR (2025-2034): 12.3%
• Largest Application Segment: Solid tumors (melanoma, head & neck, lung, colorectal)
• Fastest-Growing Segment: Combination immunotherapy + oncolytic adenovirus regimens
Therapeutic & Clinical Insights
1. Mechanism of Action
Oncolytic adenoviruses:
• Selectively replicate in tumor cells
• Cause tumor cell lysis
• Release tumor-associated antigens
• Activate innate and adaptive immune responses
• Enhance response to checkpoint inhibitors
This makes them highly valuable in treatment-resistant tumors.
2. Lead Clinical Pipeline Areas
Active clinical development is focused on:
• Melanoma
• Glioblastoma
• Pancreatic cancer
• Colorectal cancer
• NSCLC
• Hepatocellular carcinoma
3. Types of Oncolytic Adenoviruses
• Genetically modified replication-competent adenoviruses
• Armed adenoviruses expressing cytokines (GM-CSF, IL-12, TNF-α)
• Conditionally replicating adenoviruses (CRAds)
• Tumor-selective promoter-controlled constructs
Market Growth Drivers
1. Increasing Clinical Success of Virotherapy
Strong results in early- and mid-stage trials support oncologists' confidence in adenovirus-based therapeutics.
2. Rising Adoption of Immunotherapy Combinations
Oncolytic viruses significantly improve the efficacy of:
• PD-1/PD-L1 blockade
• CTLA-4 inhibitors
• Adoptive cell therapies
• Cytokine therapies
3. Growing Investments in Viral Vector Manufacturing
Pharma and biotech companies are establishing advanced GMP virotherapy facilities.
4. Precision Gene Editing Enhancements
CRISPR, epigenetic engineering, and synthetic promoters are enabling highly tumor-specific virus designs.
5. Expansion of Personalized Cancer Medicine
Oncolytic adenoviruses can be tailored to tumor genetics and tumor microenvironment.
Market Restraints
• Manufacturing complexity & high production cost
• Limited number of globally approved virotherapies
• Regulatory challenges in gene-modified therapeutics
• Safety considerations in immunocompromised patients
• Need for specialized virotherapy-capable clinical centers
Market Opportunities
1. Development of Armed and Next-Generation Viruses
Adenoviruses expressing:
• Immune-activating cytokines
• Checkpoint blockade molecules
• Anti-angiogenic proteins
represent high-value pipeline assets.
2. Combination Therapies
The strongest commercial potential lies in combining adenoviruses with:
• Checkpoint inhibitors
• CAR-T / TCR therapies
• DNA vaccines
• Radiotherapy
3. AI-Driven Oncolytic Virus Design
Machine learning enhances viral genome optimization for safety and potency.
4. Growth in Asia Pacific Oncology Trials
China, South Korea, Japan, and Singapore are rapidly expanding virotherapy development.
5. Solid Tumors as the Main Commercial Opportunity
Especially tumors poorly responsive to immunotherapy alone.
Segmentation Overview
By Virus Type
• Genetically modified adenovirus
• Conditionally replicating adenovirus (CRAd)
• Armed oncolytic adenovirus (cytokine-expressing)
By Application
• Melanoma
• Glioblastoma
• Liver cancer
• Lung cancer
• Pancreatic cancer
• Colorectal cancer
• Prostate cancer
By Therapy Modality
• Monotherapy
• Combination with checkpoint inhibitors
• Combination with CAR-T / TCR therapies
• Combination with chemotherapy / radiation
By End User
• Hospitals & cancer centers
• Research & academic institutes
• Biotechnology companies
• Clinical trial sites
Explore Full Report here: https://exactitudeconsultancy.com/reports/71266/oncolytic-adenovirus-market
Regional Insights
North America - Largest Market
Strong clinical trial ecosystem, high immunotherapy adoption, and robust biotech investment.
Europe - Strong Regulatory & Research Support
Germany, UK, France, and the Nordics lead in advanced viral oncology programs.
Asia Pacific - Fastest Growth
China, Japan, and South Korea expanding virotherapy R&D and GMP manufacturing.
Latin America - Growing Interest
Increasing clinical participation in immuno-virotherapy trials.
Middle East & Africa - Emerging Market
Gradual adoption as cancer centers modernize.
Competitive Landscape
Leading companies in the Oncolytic Adenovirus Market include:
• DNAtrix
• ONCOS Therapeutics / Targovax
• Sorrento Therapeutics
• CG Oncology
• Lokon Pharma
• Merck
• Bristol Myers Squibb
• Takeda
• Novartis
• Shanghai Sunway Biotech
Focus areas include:
• Enhanced tumor selectivity
• Immune-stimulatory engineered viruses
• Next-generation adenovirus chassis
• Virotherapy + immunotherapy combinations
Recent Market Developments
• Expansion of phase II and phase III trials in solid tumors
• Next-generation adenoviruses expressing GM-CSF, IL-12, and IFN-γ advancing in pipeline
• Positive data on adenovirus + PD-1 inhibitor combinations
• Growing investment in GMP viral vector manufacturing facilities
• AI-optimized oncolytic adenovirus design showing promising results
Future Outlook (2025-2034)
The Oncolytic Adenovirus Market will grow rapidly as:
• Combination immunotherapy becomes standard practice
• Gene-engineered adenoviruses achieve higher potency & safety
• Viral oncology manufacturing capacity expands globally
• Regulatory pathways for virotherapy become clearer
• Precision virotherapy and AI-engineered viruses enter commercialization
By 2034, the market is expected to reach USD 389 million, driven by breakthroughs in engineered virotherapy and rising oncology demand.
This report is also available in the following languages : Japanese (腫瘍溶解性アデノウイルス市場), Korean (종양용해성 아데노바이러스 시장), Chinese (溶瘤腺病毒市场), French (Marché des adénovirus oncolytiques), German (Markt für onkolytische Adenoviren), and Italian (Mercato dell'adenovirus oncolitico), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71266
Our More Reports:
Oncolytic Virus Therapy Market
https://exactitudeconsultancy.com/reports/47948/oncolytic-virus-therapy-market
Intratumoral Cancer Therapies Market
https://exactitudeconsultancy.com/reports/59107/global-intratumoral-cancer-therapies-market
Adenovirus ELISA Kits Market
https://exactitudeconsultancy.com/reports/56726/global-adenovirus-elisa-kits-market
Adenovirus Antigen Rapid Tests Market
https://exactitudeconsultancy.com/reports/59217/global-adenovirus-antigen-rapid-tests-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Adenovirus Market is projected to reach USD 389 million by 2034 here
News-ID: 4309956 • Views: …
More Releases from Exactitude Consultancy
Warts Market is Expected to reach USD 3.0-3.3 billion by 2032, reflecting a CAGR …
Market Overview
The global Warts market is expanding steadily as demand increases for dermatology treatments targeting HPV-related skin growths. Warts-caused by human papillomavirus (HPV) infection-are highly prevalent across all age groups and commonly appear on the hands, feet, and genital areas. Rising awareness, growing OTC product usage, and technological advancements in dermatologic procedures are driving market growth.
The global Warts market was valued at USD 1.9-2.1 billion in 2024. With increasing adoption…
Idiopathic Inflammatory Myositis (IIM) Market is projected to reach USD 2.43 bil …
The global Idiopathic Inflammatory Myositis (IIM) Market was valued at USD 1.18 billion in 2024 and is projected to reach USD 2.43 billion by 2034, growing at a CAGR of 7.5% from 2025 to 2034. Market growth is driven by increasing recognition of autoimmune myopathies, advances in autoantibody testing, rising demand for biologics and immunomodulatory therapies, and expansion of multidisciplinary rheumatology-neuromuscular care.
Download Full PDF Sample Copy of Market Report @…
Varicose Ulcer Market is projected to reach USD 4.5-5.0 billion by 2032, registe …
Market Overview
The Varicose Ulcer market is expanding steadily due to the rising global prevalence of chronic venous insufficiency (CVI), aging populations, diabetes, and obesity-major contributors to lower-limb venous ulcers. Varicose ulcers (venous leg ulcers) account for the majority of chronic wound cases worldwide, creating sustained demand for advanced wound care, compression therapy, and minimally invasive venous procedures.
The global Varicose Ulcer market was valued at USD 2.9-3.2 billion in 2024. With…
Soft Tissue Defect Market is projected to reach USD 7.0-8.0 billion by 2032, reg …
Market Overview
The Soft Tissue Defect market is expanding rapidly due to rising surgical volumes, increasing traumatic injuries, growing prevalence of chronic wounds, and advancements in regenerative medicine. Soft tissue defects occur due to trauma, tumor excision, infections, burns, congenital anomalies, and postoperative complications-requiring reconstruction using grafts, flaps, scaffolds, or tissue-engineered solutions.
The global Soft Tissue Defect market was valued at USD 4.5-5.0 billion in 2024. Driven by innovation in biologics, synthetic…
More Releases for Oncolytic
Prominent Oncolytic Virus Therapy Market Trend for 2025: Accelerating Oncolytic …
Which drivers are expected to have the greatest impact on the over the oncolytic virus therapy market's growth?
The rise in cancer incidences is likely to fuel the expansion of the oncolytic virus therapy market. Oncolytic virus therapy is gaining traction as an appealing approach to treating cancer- a collection of diseases marked by abnormal cell growth and proliferation. This therapeutic strategy effectively targets and eliminates cancer cells, while also triggering…
Enhancing the Immune Response with Oncolytic Virus Therapy
Oncolytic virus therapy is revolutionizing cancer treatment by harnessing the unique characteristics of viruses to specifically target and destroy cancer cells. This cutting-edge approach represents a significant advancement in cancer care, offering renewed hope for patients with different types of cancer.
Download Report:
https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas
The essence of oncolytic virus therapy is based on genetically modified viruses that can selectively attack and kill cancer cells while leaving healthy tissue unharmed. These engineered viruses take…
Creative Biolabs Unleashes Solutions to Validate Oncolytic Virotherapy
Creative Biolabs introduces safety and efficacy validation strategies for oncolytic virotherapy.
New York, USA - June 17, 2024 - Oncolytic virotherapy appears as a new paradigm in cancer immunotherapy that enrolls specifically engineered viruses to selectively infect and kill cancer cells, some of which have marched into clinical trials, like adenoviruses, HSV, reovirus, vaccinia virus, and measles. With so many other candidates still on their preclinical journey, the requests to validate…
Oncolytic Virus Competitive Landscape 2023 (Updated)
DelveInsight's, "Oncolytic Virus Competitive Landscape 2023" report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
